146 related articles for article (PubMed ID: 21181095)
1. Na+/K+-ATPase α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin.
Li H; Wang P; Gao Y; Zhu X; Liu L; Cohen L; Meng Z; Yang P
Oncol Rep; 2011 Mar; 25(3):825-30. PubMed ID: 21181095
[TBL] [Abstract][Full Text] [Related]
2. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
4. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
5. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na
Lan YL; Wang X; Lou JC; Xing JS; Yu ZL; Wang H; Zou S; Ma X; Zhang B
Biomed Pharmacother; 2018 Jul; 103():204-215. PubMed ID: 29653366
[TBL] [Abstract][Full Text] [Related]
6. Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma via Modulating the ATP1A1/CA2 Axis.
Huang CJ; Zhang CY; Zhao YK; Wang D; Zhuang L; Qian L; Xie L; Zhu Y; Meng ZQ
Am J Chin Med; 2023; 51(2):461-485. PubMed ID: 36655687
[TBL] [Abstract][Full Text] [Related]
7. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Gao Y; Li HX; Xu LT; Wang P; Xu LY; Cohen L; Yang PY; Gu K; Meng ZQ
Mol Biol Rep; 2012 Feb; 39(2):1683-9. PubMed ID: 21617941
[TBL] [Abstract][Full Text] [Related]
8. Na+/K+-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma.
Zhuang L; Xu L; Wang P; Jiang Y; Yong P; Zhang C; Zhang H; Meng Z; Yang P
Oncotarget; 2015 Sep; 6(29):28183-93. PubMed ID: 26334094
[TBL] [Abstract][Full Text] [Related]
9. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells.
Tsai SC; Yang JS; Peng SF; Lu CC; Chiang JH; Chung JG; Lin MW; Lin JK; Amagaya S; Wai-Shan Chung C; Tung TT; Huang WW; Tseng MT
Int J Oncol; 2012 Oct; 41(4):1431-42. PubMed ID: 22858649
[TBL] [Abstract][Full Text] [Related]
10. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding.
Fu R; Yu F; Wu W; Liu J; Li J; Guo F; Xu L; Wang F; Cui X
Int Immunopharmacol; 2021 Dec; 101(Pt B):108195. PubMed ID: 34678691
[TBL] [Abstract][Full Text] [Related]
11. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway.
Gai JQ; Sheng X; Qin JM; Sun K; Zhao W; Ni L
Int J Oncol; 2016 Jan; 48(1):338-48. PubMed ID: 26648168
[TBL] [Abstract][Full Text] [Related]
12. Blocking autophagy enhances the apoptosis effect of bufalin on human hepatocellular carcinoma cells through endoplasmic reticulum stress and JNK activation.
Hu F; Han J; Zhai B; Ming X; Zhuang L; Liu Y; Pan S; Liu T
Apoptosis; 2014 Jan; 19(1):210-23. PubMed ID: 24114361
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Na+,K(+)-ATPase inhibition in K562 cell differentiation induced by bufalin.
Numazawa S; Shinoki MA; Ito H; Yoshida T; Kuroiwa Y
J Cell Physiol; 1994 Jul; 160(1):113-20. PubMed ID: 8021291
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
15. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC
Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670
[TBL] [Abstract][Full Text] [Related]
16. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
17. A Novel Bufalin Derivative Exhibited Stronger Apoptosis-Inducing Effect than Bufalin in A549 Lung Cancer Cells and Lower Acute Toxicity in Mice.
Liu M; Feng LX; Sun P; Liu W; Wu WY; Jiang BH; Yang M; Hu LH; Guo DA; Liu X
PLoS One; 2016; 11(7):e0159789. PubMed ID: 27459387
[TBL] [Abstract][Full Text] [Related]
18. Natriuretic effect of bufalin in isolated rat kidneys involves activation of the Na+-K+-ATPase-Src kinase pathway.
Arnaud-Batista FJ; Costa GT; Oliveira IM; Costa PP; Santos CF; Fonteles MC; Uchôa DE; Silveira ER; Cardi BA; Carvalho KM; Amaral LS; Pôças ES; Quintas LE; Noël F; Nascimento NR
Am J Physiol Renal Physiol; 2012 Apr; 302(8):F959-66. PubMed ID: 22237798
[TBL] [Abstract][Full Text] [Related]
19. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
20. A cardiotonic steroid bufalin-induced differentiation of THP-1 cells. Involvement of Na+, K(+)-ATPase inhibition in the early changes in proto-oncogene expression.
Numazawa S; Inoue N; Nakura H; Sugiyama T; Fujino E; Shinoki M; Yoshida T; Kuroiwa Y
Biochem Pharmacol; 1996 Jul; 52(2):321-9. PubMed ID: 8694857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
